VAISALA CORPORATIONSTOCK EXCHANGE RELEASE 25.7.2025 Vaisala Corporation: Share Repurchase 25.7.2025 In the Helsinki Stock Exchange Trade date 25.7.2025 Bourse trade Buy Share VAIAS Amount 2 800SharesAverage price/ share 46,9821EURTotal cost 131 549,88EUR Vaisala Corporation now holds a total of 119 818 shares<td colspan="2" s ...

Key Takeaways ISRG procedures rose 17% in Q2, led by general surgery and a rebound in China.Gross margin fell 200bps to 67.9% due to FX, logistics, and da Vinci 5 ramp-up effects.ISRG held FY25 margin guidance as digital tools, automation, and I&A growth offset headwinds.Intuitive Surgical (ISRG) delivered a solid second-quarter 2025 performance, with procedure volumes up 17% year over year, maintaining double-digit growth across key U.S. and international markets. The performance was led by continued stren ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Bio-Rad Laboratories (BIO) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The earnings report, which is expected to be released on July 31, might help the stock move higher if these key numbers are better than expecta ...

As investors, we all pursue a total return strategy, whether we admit it or not. We all shuffle among equities, bonds, commodities, and alternative assets in the hope of generating as much of a total return as we can. WeWith an investment banking cash and derivatives trading background, Binary Tree Analytics ('BTA') aims to provide transparency and analytics in respect to capital markets instruments and trades. BTA focuses on CEFs, ETFs and Special Situations, and aims to deliver high annualized returns wit ...

长沙晚报全媒体记者 朱泽寰 7月14日，望城经开集团子公司振望公司在上海证券交易所成功非公开发行科技创新公司债券，发行规 模5亿元，全场认购倍数3.88倍，彰显了资本市场对望城经开区的高度认可。 作为长沙最年轻的国家级经开区，望城经开区在2025年上半年，围绕强链建群、项目招引建设、企业服 务与创新创业精准发力，累计规模工业总产值同比增长10.51%，规模工业增加值同比增长12.2%，多项 经济指标逆势上扬，呈现出强劲的发展韧性与潜力。 延链建群，奏响产业发展"奋进曲" 望城经开区各企业的生产车间内，智能终端产品从零部件到整机的组装一气呵成，新型合金材料在流水 线上完成精密加工，健康食品的标准化生产有序推进……"两主一特"产业上半年分别交出产值同比增长 5.0%、14.7%、10.9%的亮眼答卷。 在智能终端产品方面，比亚迪电子发挥龙头引领作用，一期项目连续多年产值稳定在百亿元以上，二期 项目签约落地并加速建设，计划打造成高端智能手机等终端产品生产基地，投产后可新增年产量1000万 台的产能，并带动众多上下游配套企业集聚，强化智能终端产业链。 除了比亚迪的高歌猛进，利亚德长沙LED产业园项目也在5月迎来又一突 ...

Second-quarter highlights Orders of $7.0 billion, including $3.5 billion of IET orders.RPO of $34.0 billion, including record IET RPO of $31.3 billion.Revenue of $6.9 billion, down 3% year-over-year.Attributable net income of $701 million.GAAP diluted EPS of $0.71 and adjusted diluted EPS* of $0.63.Adjusted EBITDA* of $1,212 million, up 7% year-over-year.Cash flows from operating activities of $510 million and free cash flow* of $239 million.Returns to shareholders of $423 million, including $196 million of ...

Core Insights - SS Innovations International, Inc. has successfully completed the world's first intercontinental robotic cardiac telesurgery, showcasing the capabilities of its SSi Mantra 3 surgical robotic system [1][4][6] Company Overview - SS Innovations is dedicated to making robotic surgery affordable and accessible globally, with a focus on innovative surgical robotic technologies [1][8] - The company has received regulatory approval from India's Central Drugs Standard Control Organization for both teleproctoring and telesurgery, distinguishing it from other surgical robotic companies [7] Surgical Achievements - The recent cardiac procedure involved a robotic atrial septal defect closure performed remotely from Strasbourg, France to Indore, India, covering a distance of over 4,000 miles [2][3] - To date, SS Innovations has completed 35 telesurgeries, including 10 cardiac procedures, demonstrating the effectiveness of the SSi Mantra system in complex surgeries [6] Technological Features - The SSi Mantra surgical robotic system includes advanced features such as modular robotic arms, a 3D 4K monitor, and the ability to superimpose 3D diagnostic imaging models, enhancing surgical precision and safety [12]

Revvity (RVTY) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 28, might help the stock move higher if these key numbers are better than expectations. On ...

Core Viewpoint Teledyne Technologies is expected to report strong second-quarter 2025 results, with revenue and earnings growth driven by improved sales across all business segments, including Digital Imaging, Instrumentation, Aerospace & Defense Electronics, and Engineered Systems [1][6][7]. Group 1: Revenue Expectations - Teledyne Technologies is projected to post second-quarter revenue of $1.47 billion, reflecting a year-over-year increase of 7.1% [8]. - The Digital Imaging segment's revenues are estimated at $756.5 million, indicating a year-over-year growth of 2.3% [2]. - The Instrumentation segment is expected to generate revenues of $358.5 million, representing a year-over-year rise of 7.5% [3]. - The Aerospace & Defense Electronics unit's revenues are projected at $240.9 million, implying a significant growth of 23.9% compared to the previous year [4]. - Engineered Systems' revenues are estimated at $110.2 million, showing a rise of 3.2% from the year-ago quarter [5]. Group 2: Earnings Expectations - The consensus estimate for second-quarter earnings per share (EPS) is pegged at $5.01, indicating a growth of 9.4% from the prior-year figure [8]. - Positive synergies from the acquisitions of Micropac and Qioptiq are expected to contribute favorably to Teledyne's earnings performance [6][7]. Group 3: Market Position and Predictions - Teledyne Technologies has delivered a four-quarter earnings surprise of 2.69% on average, suggesting a history of exceeding earnings expectations [1]. - The company currently holds a Zacks Rank of 4 (Sell), indicating a less favorable outlook compared to peers [10]. - The Earnings ESP for Teledyne is +1.22%, but the model does not predict a definitive earnings beat this time [9].

Core Viewpoint - Analysts project that Thermo Fisher Scientific (TMO) will report quarterly earnings of $5.22 per share, reflecting a 2.8% decline year over year, with revenues expected to reach $10.65 billion, a 1% increase from the same quarter last year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.2% over the past 30 days, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock price performance [3]. Revenue Projections - Analysts estimate 'Revenues- Laboratory Products and Biopharma Services' at $5.74 billion, a decrease of 0.2% year over year [5]. - 'Revenues- Specialty Diagnostics' are projected to reach $1.14 billion, indicating a 2.5% increase year over year [5]. - 'Revenues- Life Sciences Solutions' are expected to be $2.40 billion, reflecting a 2.1% increase year over year [5]. - 'Revenues- Analytical Instruments' are estimated at $1.79 billion, showing a 0.7% increase year over year [6]. - 'Geographic Revenues- Customer Location- North America' is projected at $5.56 billion, a 0.5% increase from the prior year [6]. - 'Geographic Revenues- Customer Location- Asia-Pacific' is estimated at $1.98 billion, reflecting a 0.4% increase year over year [7]. - 'Geographic Revenues- Customer Location- Other regions' is expected to reach $391.38 million, indicating a 3.3% increase year over year [7]. - 'Geographic Revenues- Customer Location- Europe' is projected at $2.69 billion, suggesting a 0.9% increase year over year [8]. Stock Performance - Over the past month, shares of Thermo Fisher have returned +8.3%, outperforming the Zacks S&P 500 composite's +5.4% change [8]. - Currently, TMO holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the overall market in the near future [8].